XNCR News

These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.

Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands at $1.9read more...

Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.read more...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT (4:00 a.m. PDT) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m...

In recent trading, shares of Xencor, Inc (Symbol: XNCR) have crossed above the average analyst 12-month target price of $29.00, changing hands for $29.33/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuatio...

Xencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2026. We are excited to present XmAb819 results at ESMO this fall and...